Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Abvc Biopharma (ABVC) over the last 14 years, with Q3 2025 value amounting to $853911.0.

  • Abvc Biopharma's Cash & Current Investments rose 1091.58% to $853911.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $853911.0, marking a year-over-year increase of 1091.58%. This contributed to the annual value of $863815.0 for FY2024, which is 2051.33% up from last year.
  • Abvc Biopharma's Cash & Current Investments amounted to $853911.0 in Q3 2025, which was up 1091.58% from $1.1 million recorded in Q2 2025.
  • Abvc Biopharma's Cash & Current Investments' 5-year high stood at $6.7 million during Q4 2021, with a 5-year trough of $716780.0 in Q4 2023.
  • In the last 5 years, Abvc Biopharma's Cash & Current Investments had a median value of $1.2 million in 2023 and averaged $1.8 million.
  • In the last 5 years, Abvc Biopharma's Cash & Current Investments surged by 272003.54% in 2021 and then tumbled by 7800.92% in 2022.
  • Quarter analysis of 5 years shows Abvc Biopharma's Cash & Current Investments stood at $6.7 million in 2021, then plummeted by 78.01% to $1.5 million in 2022, then tumbled by 51.16% to $716780.0 in 2023, then increased by 20.51% to $863815.0 in 2024, then dropped by 1.15% to $853911.0 in 2025.
  • Its Cash & Current Investments was $853911.0 in Q3 2025, compared to $1.1 million in Q2 2025 and $759568.0 in Q1 2025.